Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.

Participants needed: 244
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Taiho Pharmaceutical Co., Ltd.Updated: Aug 19, 2026Locations: 29
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 [+19]

Investigational agents or anticancer therapy within 5 half-lives prior to the fi... [+6]

Read more
Status: Recruiting

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

\[Tolerability Assessment Part\] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2. \[Expansion Assessment Part\] The purpose is to compare the total AUC for AZA after administration of ASTX030 with that after administration of AZA injection at 75 mg/m2.

Participants needed: 59
Trial details
Phase: Phase 1Age: 20+Biological sex: AllType: InterventionalSponsor: Taiho Pharmaceutical Co., Ltd.Updated: Aug 10, 2026Locations: 10
Eligibility criteria

Patients aged 20 years or older [+19]

Patients who are unlikely to respond to AZA [+38]

Read more
Status: Recruiting

AB122 Platform Study

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

Participants needed: 917
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Taiho Pharmaceutical Co., Ltd.Updated: Aug 5, 2026Locations: 9
Eligibility criteria

Is male or female aged ≥ 18 years at the time of informed consent; Willing and a... [+54]

Clinically significant history or current evidence of cardiac arrhythmia and/or... [+21]

Read more
Status: Recruiting

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer

Participants needed: 784
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Taiho Pharmaceutical Co., Ltd.Updated: Jul 17, 2026Locations: 21
Eligibility criteria

Has histologically confirmed unresectable or advanced biliary tract (i.e. intrah... [+5]

History and/or current evidence of clinically significant nontumor-related alter... [+3]

Read more